IMAC

Theralink® and IMAC Holdings announce receipt and response to the Securities and Exchange Commission comments on the previously filed Form S4

Retrieved on: 
Monday, November 13, 2023
Acquisition, Security (finance), Proteomics, Form, INC, FDA, IMAC, BACK, Cancer, Mergers and acquisitions, Medicare, OTC, Golden

A Form S-4 is a registration statement that the Securities and Exchange Commission requires all reporting companies to file in order to publicly offer new securities pursuant to a merger or acquisition.

Key Points: 
  • A Form S-4 is a registration statement that the Securities and Exchange Commission requires all reporting companies to file in order to publicly offer new securities pursuant to a merger or acquisition.
  • The Companies previously filed the S-4 on September 29th and received comments from the SEC in late October.
  • Theralink’s Chief Executive Officer, Faith Zaslavsky previously stated “The filing of the Form S-4 is a major milestone, as it signifies Theralink and IMAC have reached a definitive agreement and that the transaction is moving forward.
  • The result of the Merger will be a well-positioned proteomics pure play squarely focused on the next generation of cancer care and protein analysis, an opportunity that all stakeholders in our companies are highly excited about.

Brett Seybold Elected to Federal Home Loan Bank of Dallas Board of Directors

Retrieved on: 
Monday, November 20, 2023
Banking, Professional Services, Finance, USAA, FHLB, Multimedia, Federal Home Loan Banks, Haven of Hope Hospital, IMAC, Committee on Finance, Management, Hope

The Federal Home Loan Bank of Dallas (FHLB Dallas) is pleased to announce the election of Brett Seybold to the FHLB Dallas Board of Directors (Board) as a member director representing Texas.

Key Points: 
  • The Federal Home Loan Bank of Dallas (FHLB Dallas) is pleased to announce the election of Brett Seybold to the FHLB Dallas Board of Directors (Board) as a member director representing Texas.
  • View the full release here: https://www.businesswire.com/news/home/20231120408519/en/
    Brett Seybold, senior vice president and treasurer of United Services Automobile Association, will begin his four-year term on the FHLB Dallas Board starting January 1, 2024.
  • Seybold’s experience and expertise are a great fit and complement the existing Board,” said FHLB Dallas President and CEO Sanjay Bhasin.
  • “We are fortunate to have him.”
    Since 2021, Mr. Seybold has served as the FHLB Dallas Insurance Member Advisory Council Chair (IMAC).

2023 World Intelligent Manufacturing Conference to Open Soon with Synchronous Offline Exhibition

Retrieved on: 
Monday, December 4, 2023
Assistant, Yangtze Delta, Record, Nanjing International Expo Center, Multimedia, Ecology, Union, Information technology, IMAC, Digital, Intelligence, Conference, Exhibition, ICIM, CAST, Innovation

The conference will also host five major special events, including the Sino-French Digitalization Forum for Manufacturing, the inaugural annual meeting of the ICIM. The conference will focus on four major themes -- standards and evaluation, application and demonstration promotion, supply and solution, and innovation and ecology -- and will organize 15 professional forums.

Key Points: 
  • NANJING, China, Dec. 4, 2023 /PRNewswire/ -- On December 1, the second press conference for the 2023 World Intelligent Manufacturing Conference was held.
  • This year's conference is themed "Intelligent, Digital and Connected Transformation, Digital-real Economy Integration and Innovation", according to the Organizing Committee.
  • The "2023 World Top 10 Technological Advancements in Intelligent Manufacturing" and the "2023 Top 10 Technological Advancements in Chinese Intelligent Manufacturing" will be unveiled during the significant announcement session.
  • As part of the conference's supporting events, the third Intelligent Manufacturing Innovation Competition's achievements will be showcased during the conference.

Theralink Announces Filing of Form S-4; Merger with IMAC Holdings Expected During Q4 2023

Retrieved on: 
Wednesday, October 4, 2023
Proteomics, Medicare, Mergers and acquisitions, Acquisition, OTC, Form, Security (finance), Breast cancer, IMAC

Upon regulatory approval, Theralink and IMAC expect to complete the Merger by the end of the current quarter.

Key Points: 
  • Upon regulatory approval, Theralink and IMAC expect to complete the Merger by the end of the current quarter.
  • Theralink and IMAC will be holding an investor call to provide additional insight and commentary on the Merger, which will create an exciting new NASDAQ-listed company focused on end-to-end proteomics testing.
  • The SEC reviews a Form S-4 filing to ensure that it is complete and accurate and that a merger complies with all applicable laws and regulations.
  • Once the SEC has approved the Form S-4 filing, the companies can hold shareholder votes to approve a merger.

IMAC Holdings Announces $4.3 Million Private Placement of Convertible Preferred Stock and Warrants Priced at the Market

Retrieved on: 
Wednesday, July 26, 2023
Marketing, Regulation D, The Act, Securities and Exchange Commission (Nigeria), Sale, OTC, Warrant, Security (finance), United, IMAC, BACK, Series

IMAC sold an aggregate of 2,500 shares of its Series A-1 Convertible Preferred Stock, stated value $1,000 per share, 1,800 shares of its Series A-2 Convertible Preferred Stock, stated value $1,000 per share, and Warrants to purchase up to 62,271,063 shares of its common stock for aggregate gross proceeds of $4,300,000 before deducting placement agent fees and other offering expenses.

Key Points: 
  • IMAC sold an aggregate of 2,500 shares of its Series A-1 Convertible Preferred Stock, stated value $1,000 per share, 1,800 shares of its Series A-2 Convertible Preferred Stock, stated value $1,000 per share, and Warrants to purchase up to 62,271,063 shares of its common stock for aggregate gross proceeds of $4,300,000 before deducting placement agent fees and other offering expenses.
  • The shares of A-1 Convertible Preferred Stock, shall bear a 12% dividend, and are initially convertible into an aggregate of 22,893,773 shares of common stock of the Company, and the shares of Series A-2 Convertible Preferred Stock are initially convertible into an aggregate of 16,483,517 shares of common stock of the Company, in each case, at a conversion price of $0.1092 per share.
  • The Warrants have an exercise price of $0.1092 per share, are exercisable immediately, and will expire five years from the date of shareholder approval of this private placement.
  • The Company has agreed to file a registration statement with the SEC covering the resale of the shares of the common stock underlying the Series A-1 Preferred Stock, Series A-2 Preferred Stock and A Warrants no later than 45 days following the closing of the planned merger.

IMAC Holdings Annual Meeting of Shareholders Reminder

Retrieved on: 
Wednesday, June 28, 2023
Internet, Proxy, Rehabilitation, Annual general meeting, Control, IMAC, BACK, Security (finance), Holding company

FRANKLIN, Tenn., June 28, 2023 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, reminds its shareholders that its Annual Meeting will be held July 5, 2023 at 11:00 am, local time, in Franklin, Tennessee.

Key Points: 
  • Shareholders are reminded to vote their shares prior to the proxy voting deadline of 7:00pm on July 4, 2023
    FRANKLIN, Tenn., June 28, 2023 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, reminds its shareholders that its Annual Meeting will be held July 5, 2023 at 11:00 am, local time, in Franklin, Tennessee.
  • IMAC shareholders are encouraged to read the Proxy Statement filed in connection with the Meeting in detail and cast their votes prior to the proxy voting deadline.
  • You will find the Control number and the internet address in your Notice of Internet Availability.
  • Registered shareholders may be able to vote through their broker of record.

Theralink Technologies Appoints Faith Zaslavsky as Chief Executive Officer

Retrieved on: 
Tuesday, June 27, 2023
Hereditary nonpolyposis colorectal cancer, Cancer, Breast, Research, Genomics, Patient, Physician, Risk, OTC, Knowledge, BRCA2, Breast cancer, Gene, IMAC, BACK, Management, Faith

Golden, Colorado, June 27, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a novel phosphoprotein and protein assay for breast cancer in the process of merging with IMAC Holdings, Inc. (NASDAQ: BACK), today announces the appointment of Faith Zaslavsky as its new Chief Executive Officer.

Key Points: 
  • Golden, Colorado, June 27, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a novel phosphoprotein and protein assay for breast cancer in the process of merging with IMAC Holdings, Inc. (NASDAQ: BACK), today announces the appointment of Faith Zaslavsky as its new Chief Executive Officer.
  • Ms. Zaslavsky, who has served as the Company’s President and Chief Operating Officer since December 2022, will assume this role effective June 26, 2023, replacing Mick Ruxin, M.D., who will transition to Theralink’s Chief Medical Officer.
  • As Chief Executive Officer of Theralink, Ms. Zaslavsky will be tasked with leveraging her prior successes to spearhead commercialization of the Theralink® Reverse Phase Protein Array assays, a next generation of genomic technology used to guide personalized cancer therapeutics.
  • Faith Zaslavsky stated, “On behalf of our executive leadership team, I want to thank Mick for his innumerable contributions and dedicated years of service to Theralink.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BACK, GNL, RTL

Retrieved on: 
Sunday, June 4, 2023
Sale, Fraud, NYSE, Advertising, IMAC, Renting, Security (finance)

If you are an IMAC shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an IMAC shareholder, click here to learn more about your rights and options .
  • Per the terms of the proposed transaction, Necessity Retail stockholders will receive 0.670 shares of Global Net for each common share of Necessity Retail.
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GHL, DM, BACK

Retrieved on: 
Sunday, May 28, 2023
Greenhill & Co., Metal, Desktop Metal, Sale, Advertising, Fraud, NYSE, IMAC, Security (finance), Stratasys

If you are a Greenhill shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Greenhill shareholder, click here to learn more about your rights and options .
  • If you are a Desktop Metal shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

THERALINK INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Theralink Technologies, Inc. - THER

Retrieved on: 
Wednesday, May 31, 2023
Class Action Lawsuit, Professional Services, Legal, Sale, OTC, KSF, IMAC, BACK

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Key Points: 
  • Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Theralink Technologies, Inc. (OTC: THER) with IMAC Holdings, Inc. (NasdaqCM: BACK) pursuant to which Theralink will a wholly-owned subsidiary of IMAC.
  • KSF is seeking to determine whether the merger and the process that led to it are adequate and fair to the Company’s shareholders.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .